Pharma
The U.S. imaging services market is on a significant upward trajectory, valued at $144.8 billion in 2023 and projected to grow to $192.9 billion by 2030. This expansion is fueled by an increasing number of cancer and cardiac cases, along with continuous advancements in medical imaging technologies. As diagnostic imaging remains essential to modern medicine, the sector is expected to grow by nearly 6% annually from 2022 to 2027, supported by the rise of diagnostic centers and an aging population that will soon surpass 74 million people over the age of 65.
Segmed, Inc. is advancing the medical imaging industry with a unique strategy that leverages the potential of varied imaging data for artificial intelligence development and clinical research. Segmed has created a platform that combines a variety of de-identified imaging data by working with hundreds of healthcare providers. With the help of this platform, innovators may create comprehensive cohorts in their own settings, bringing a new degree of accuracy to patient treatment and advancing the field of precision medicine.
To support its vision, Segmed recently secured $10.4 million in Series A funding. This oversubscribed round was led by iGan Partners and Advocate Health, with additional backing from Castellan Group, Engine Health Capital, Bold Brain Ventures, Fox Chase Cancer Center, and Y Combinator. The funding represents not just financial backing but a strong endorsement from key players in both healthcare and venture capital.
